Viking Therapeutics Inc (VKTX)
67.00
-2.06
(-2.99%)
USD |
NASDAQ |
May 17, 16:00
67.13
+0.14
(+0.20%)
After-Hours: 20:00
Viking Therapeutics SG&A Expense (Annual): 37.02M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 37.02M |
| December 31, 2022 | 16.12M |
| December 31, 2021 | 10.70M |
| December 31, 2020 | 10.73M |
| December 31, 2019 | 9.128M |
| December 31, 2018 | 7.121M |
| Date | Value |
|---|---|
| December 31, 2017 | 5.329M |
| December 31, 2016 | 4.847M |
| December 31, 2015 | 5.030M |
| December 31, 2014 | 1.245M |
| December 31, 2013 | 0.0895M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
9.128M
Minimum
2019
37.02M
Maximum
2023
16.74M
Average
10.73M
Median
2020
SG&A Expense (Annual) Benchmarks
| Amgen Inc | 6.179B |
| Eli Lilly and Co | 6.941B |
| Pfizer Inc | 14.77B |
| Madrigal Pharmaceuticals Inc | 108.15M |
| Terns Pharmaceuticals Inc | 39.06M |